Priority Health

MEDICAL POLICY No. 91314-R13

ELECTROPHYSIOLOGY TESTING & CATHETER ABLATION FOR CARDIAC ARRHYTHMIAS

Effective Date: December 1, 2024	**Review Dates: 1/93, 12/99, 12/01, 12/02, 2/03, 1/04, 3/04, 3/05, 2/06, 8/06, 2/07, 4/07, 4/08, 4/09, 4/10, 4/11, 4/12, 4/13, 5/14, 5/15, 5/16, 5/17, 5/18, 11/18, 11/19, 11/20, 11/21, 11/22, 11/23, 11/24**
Date of Origin: November 12, 1992	**Status: Current**

Summary of Changes

Additions:

- Added the following exclusion: Use of an active esophageal cooling device (e.g. ensoETM® (Attune Medical)) during cardiac catheter ablation is considered experimental, investigational or unproven.

I. POLICY/CRITERIA

A. Electrophysiology (EP) testing does not require prior authorization.

B. Medical necessity for catheter ablation for cardiac arrhythmias is determined through InterQual® criteria.

C. Exclusions:

- High-intensity focused ultrasound (HIFU), (e.g. the Epicor™ system) as a stand-alone ablative procedure for atrial fibrillation is considered investigational.
- Use of an active esophageal cooling device (e.g. ensoETM® (Attune Medical)) during cardiac catheter ablation is considered experimental, investigational or unproven.

II. MEDICAL NECESSITY REVIEW

Prior authorization for certain drugs, services, procedures, and devices may or may not be required. In cases where prior authorization is required, providers will submit a request demonstrating that a drug, service, procedure, or device is medically necessary. For more information, please refer to the Priority Health Provider Manual.

III. APPLICATION TO PRODUCTS

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

- **HMO/EPO:** ***This policy applies to insured HMO/EPO plans.***
- **POS:** ***This policy applies to insured POS plans.***
- **PPO:** ***This policy applies to insured PPO plans.***
- **ASO:** ***For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.***
- **INDIVIDUAL:** ***For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.***
- **MEDICARE:** ***Coverage is determined by the Centers for Medicare and Medicaid Services (CMS and/or the Evidence of Coverage (EOC); if a coverage determination has not been adopted by CMS, this policy applies.***
- **MEDICAID/HEALTHY MICHIGAN PLAN:** ***For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the Michigan Medicaid Fee Schedule located at: http://www.michigan.gov/mdch/0,1607,7-132-2945_42542_42543_42546_42551-159815--,00.html. If there is a discrepancy between this policy and the Michigan Medicaid Provider Manual located at: http://www.michigan.gov/mdch/0,1607,7-132-2945_5100-87572--,00.html, the Michigan Medicaid Provider Manual will govern. If there is a discrepancy or lack of guidance in the Michigan Medicaid Provider Manual, the Priority Health contract with Michigan Medicaid will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.***

IV. DESCRIPTION

Atrial fibrillation (AF) is the most commonly diagnosed cardiac rhythm disturbance, with an incidence of 0.4% in the general population. AF occurs in a high percentage of patients with mitral valve (MV) disease, although it can also occur in individuals with no associated cardiac abnormalities. It is characterized by loss of normal sinoatrial electrical signal and rapid, fine, uncoordinated contraction of the atria.

Atrial fibrillation is associated with morbidity and mortality despite therapy with current antiarrhythmic drugs. Even the best available medical therapy only yields a 50-60 percent annual success rate in maintaining sinus rhythm. Side effects of these drugs can be problematic. Catheter ablation of arrhythmogenic foci can be performed using radiofrequency, microwave, and cryotherapy or ultrasound technology. The Cox-maze IV, sometimes called a mini-maze, is a closed chest, minimally-invasive endoscopic procedure that creates epicardial scar lines or lesions on the epicardium (the outside of the heart) that work to divert the abnormal electrical impulses in the heart. (The Cox-maze III is an open approach typically utilized only in conjunction with valve repair or replacement.) In the convergent procedure, upon completion of a Cox-maze IV, endocardial ablation is performed, creating any additional necessary lesions on the interior walls of the heart. High-intensity focused ultrasound (HIFU), the Epicor™ system, may also be used for ablation in conjunction with other open heart procedures.

Initial experience with catheter ablation procedures based on a creation of linear lesions in both atria was disappointing but led to the key observation that focal triggers localized in the pulmonary veins were responsible for initiation of atrial fibrillation and are thus suitable targets for catheter ablation.

Electrical isolation of all four pulmonary veins from the left atrium provides the highest cure rates for atrial fibrillation. However, the procedure is operator dependent and is associated with a small but significant risk of pulmonary vein stenosis. Given the complexity and difficulties in ablating multiple pulmonary veins, **ablation of atrial fibrillation is not considered the initial treatment of choice or the standard of care for the treatment of atrial fibrillation.**

The optimal treatment method for patients who have idiopathic paroxysmal fibrillation appears to be left atrial catheter ablation as opposed to segmental ostial catheter ablation. Patients with chronic or persistent atrial fibrillation and patients with vago-tonic type of paroxysmal atrial fibrillation pulmonary vein isolation have a low success rate. In these subgroups and in patients with paroxysmal atrial fibrillation that does not respond to pulmonary vein isolation, an approach that involves ablation within the left atrium, it is likely but not proven to yield better results.

Active Esophageal Cooling Device

One major risk of cardiac ablation is thermal injury to the esophagus, which is a consequence of the proximity of the posterior wall of the left atrium to the anterior wall of the esophagus. There are several approaches to cooling the esophagus, including open irrigation of cold liquid inside the esophagus and closed-irrigated systems (e.g., expandable esophageal balloon). These methods have been evaluated in different small clinical trials with inconsistent results, and validation of safety and efficacy is still required. Reducing intraluminal esophageal temperature via active cooling has been proposed to minimize the risk of esophageal thermal injury during RF catheter ablation. Vasoconstriction associated with cooling may predispose to ischemia or vascular compromise to the esophagus.

The FDA granted a De Novo request for classification of Class II on September 13, 2023, to ensoETM® (Attune Medical). The FDA states the device is "Intended to reduce the likelihood of ablation related esophageal injury resulting from radiofrequency cardiac ablation procedures and provide gastric decompression and suctioning." FDA identifies this generic type of device as: "Temperature regulation device for esophageal protection during cardiac ablation procedures. This device is placed in the lumen of the esophagus to reduce the likelihood of esophageal injury or a specific adverse event during cardiac ablation procedures. The device uses temperature regulation to control the temperature of the esophagus during cardiac ablation."

The **ACC/AHA 2023 Guideline for the Diagnosis and Management of Atrial Fibrillation** (ACC/Joglar, et al., 2024) does not address esophageal cooling.

At this time, there is insufficient evidence in the peer-reviewed published literature in the form of large, well-designed randomized trials reported for the routine use of the ensoETM® esophageal cooling device to reduce ablation-related esophageal injury resulting from radiofrequency cardiac ablation procedures.

Future Studies:

It is expected that with further advances in technology and simplification of techniques, radio frequency ablation of atrial fibrillation will become a widespread procedure. Methods to reduce the risk of pulmonary veins stenosis are under development. These technological developments primarily focus on design of the catheter tip, including diameter of the catheter tip and method for delivering ablative energy. Balloon-based, ultra-sound catheters using laser and cryoablation are currently being designed, as are circular catheters through which either radiofrequency or cryo lesions can be delivered.

V. CODING INFORMATION

ICD-10 Codes that may apply:

I44.30 – I44.7	Other and unspecified atrioventricular block
I45.0 – I45.9	Other conduction disorders
I47.0 – I47.9	Paroxysmal tachycardia
I48.0 – I48.92	Atrial fibrillation and flutter
I49.0 – I49.9	Other cardiac arrhythmias
I97.190 – I97.191	Other postprocedural cardiac functional disturbances following surgery
I97.790 – I97.791	Other intraoperative cardiac functional disturbances during surgery

CPT/HCPCS Codes

93613	Intracardiac electrophysiologic 3-dimensional mapping (List separately in addition to code for primary procedure *(no PA required*)
93650	Intracardiac catheter ablation of atrioventricular node function, atrioventricular conduction for creation of complete heart block, with or without temporary pacemaker placement
93653	Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of an arrhythmia with right atrial pacing and recording, right ventricular pacing and recording, His recording with intracardiac catheter

ablation of arrhythmogenic focus; with treatment of supraventricular tachycardia by ablation of fast or slow atrioventricular pathway, accessory atrioventricular connection, cavo-tricuspid isthmus or other single atrial focus or source of atrial re-entry

93654 Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of an arrhythmia with right atrial pacing and recording, right ventricular pacing and recording, His recording with intracardiac catheter ablation of arrhythmogenic focus; with treatment of ventricular tachycardia or focus of ventricular ectopy including intracardiac electrophysiologic 3D mapping, when performed, and left ventricular pacing and recording, when performed

93655 Intracardiac catheter ablation of a discrete mechanism of arrhythmia which is distinct from the primary ablated mechanism, including repeat diagnostic maneuvers, to treat a spontaneous or induced arrhythmia (List separately in addition to code for primary procedure)

93656 Comprehensive electrophysiologic evaluation with transseptal catheterizations, insertion and repositioning of multiple electrode catheters, induction or attempted induction of an arrhythmia including left or right atrial pacing/recording, and intracardiac catheter ablation of atrial fibrillation by pulmonary vein isolation, including intracardiac electrophysiologic 3-dimensional mapping, intracardiac echocardiography with imaging supervision and interpretation, right ventricular pacing/recording, and His bundle recording, when performed

93657 Additional linear or focal intracardiac catheter ablation of the left or right atrium for treatment of atrial fibrillation remaining after completion of pulmonary vein isolation (List separately in addition to code for primary procedure)

33265 Endoscopy, surgical; operative tissue ablation and reconstruction of atria, limited (e.g., modified maze procedure), without cardiopulmonary bypass. *(No PA required)*

33266 Endoscopy, surgical; operative tissue ablation and reconstruction of atria, extensive (e.g., maze procedure), without cardiopulmonary bypass *(No PA required)*

C1732 Catheter, Electrophysiology, diagnostic/ablation 3D or vector mapping

C1886 Catheter, extravascular tissue ablation, any modality (insertable)

Not Covered

93799 Unlisted cardiovascular service or procedure *(Not covered when used for High-intensity focused ultrasound (HIFU) ablation. Explanatory notes must accompany claim)*

C1889 Implantable/insertable device, not otherwise classified *[Considered Experimental/Investigational/Unproven when used to report use of an active esophageal cooling device during cardiac catheter ablation]*

VI. REFERENCES

ACC/AHA/ESC. Atrial Fibrillation: 2006 Guidelines for Management of Patients With Atrial Fibrillation. J Am Coll Cardiol 2006; 48:854-906.

American College of Cardiology/American Heart Association. ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). J Am Coll Cardiol 2003;42:1493–531.

Blomström-Lundqvist et al. Management of Patients with Supraventricular Arrhythmias

Edwardo Saad, et al. Ablation of atrial fibrillation. Current Cardiology Reports. September 2000; 4(5).

EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA), Aliot EM, Stevenson WG, Almendral-Garrote JM, Bogun F, Calkins CH, Delacretaz E, Della Bella P, Hindricks G, Jaïs P, Josephson ME, Kautzner J, Kay GN, Kuck KH, Lerman BB, Marchlinski F, Reddy V, Schalij MJ, Schilling R, Soejima K, Wilber D. Heart Rhythm. 2009 Jun; 6(6):886-933.

Estes NA, "Ablation after ICD implantation--bridging the gap between promise and practice", N Engl J Med. 2007 Dec 27; 357(26):2717-9.

Fuster, V. et.al. ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation. Journal of the American College of Cardiology, Vol. 38, No. 4, 2001.

Haissaguerre M, et al., Electro physiological breakthroughs from the left atrium to the pulmonary veins. Circulation 2000; 102: 2463-2465.

Hayes, Inc. Evidence Analysis Research Brief. Esophageal Cooling During Left Atrial Catheter Ablation for Atrial Fibrillation. Hayes, Inc. May 20, 2024.

Morady F. Treatment of Paroxysmal Atrial Fibrillation by Pulmonary Vein Isolation. Circulation 2003; 67:567-571.

NASPE Policy Statement on Catheter Ablation; Personnel Policy Procedures and Therapeutic Recommendations. PACE 203; 26:789-799.

Natalea, et al., "First Human Experience with Pulmonary Vein Isolation using a through-the-balloon circumferential ultrasound ablation system for recurrent atrial fibrillation", Circulation 2000, 102: 1879-1882.

Oral H, et al. Catheter Ablation of Paroxysmal Atrial Fibrillation Segmental Pulmonary Vein Ostial Ablation versus Left Atrial Ablation. Circulation 2003; 108:2355-2360.

Reddy VY, et.al. "Prophylactic catheter ablation for the prevention of defibrillator therapy", N Engl J Med. 2007 Dec 27; 357(26):2657-65.

Wann LS, et. al. Heart Rhythm. 2011 Jan; 8(1):157-76. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Writing Committee Members, Joglar JA, Chung MK, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in J Am Coll Cardiol. 2024 Mar 5;83(9):959. doi: 10.1016/j.jacc.2024.01.020] [published correction appears in J Am Coll Cardiol. 2024 Jun 25;83(25):2714. doi: 10.1016/j.jacc.2024.05.033]. J Am Coll Cardiol. 2024;83(1):109-279. doi:10.1016/j.jacc.2023.08.017